Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;36:137-141

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hartley, T. R.
Right arrow Articles by Lovallo, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartley, T. R.
Right arrow Articles by Lovallo, W. R.
Related Collections
Right arrow Health policy and outcome research
Right arrow Behavioral/psychosocial - treatment
Right arrow Other hypertension
Right arrow Hypertension - basic studies
Right arrow Other etiology
Right arrow Epidemiology

(Hypertension. 2000;36:137.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Hypertension Risk Status and Effect of Caffeine on Blood Pressure

Terry R. Hartley; Bong Hee Sung; Gwendolyn A. Pincomb; Thomas L. Whitsett; Michael F. Wilson; William R. Lovallo

From the Veterans Affairs Medical Center and Departments of Psychiatry and Behavioral Sciences and Medicine (T.R.H., G.A.P., T.W., W.R.L.), University of Oklahoma Health Sciences Center, Oklahoma City; and Department of Medicine (B.H.S., M.F.W.), State University of New York and Millard Fillmore Health Care System, Buffalo.

Correspondence to William R. Lovallo, PhD, Veterans Affairs Medical Center (151A), 921 Northeast 13th St, Oklahoma City, OK 73104. E-mail bill{at}oubsci6.vahsc.ouhsc.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—We compared the acute effects of caffeine on arterial blood pressure (BP) in 5 hypertension risk groups composed of a total of 182 men. We identified 73 men with optimal BP, 28 with normal BP, 36 with high-normal BP, and 27 with stage 1 hypertension on the basis of resting BP; in addition, we included 18 men with diagnosed hypertension from a hypertension clinic. During caffeine testing, BP was measured after 20 minutes of rest and again at 45 to 60 minutes after the oral administration of caffeine (3.3 mg/kg or a fixed dose of 250 mg for an average dose of 260 mg). Caffeine raised both systolic and diastolic BP (SBP and DBP, respectively; P<0.0001 for both) in all groups. However, an ANCOVA revealed that the strongest response to caffeine was observed among diagnosed men, followed by the stage 1 and high-normal groups and then by the normal and optimal groups (SBP F4,175=5.06, P<0.0001; DBP F4,175=3.02, P<0.02). Indeed, diagnosed hypertensive men had a pre-to-postdrug change in BP that was >1.5 times greater than the optimal group. The potential clinical relevance of caffeine-induced BP changes is seen in the BPs that reached the hypertensive range (SBP >=140 mm Hg or DBP >=90 mm Hg) after caffeine. During the predrug baseline, 78% of diagnosed hypertensive men and 4% of stage 1 men were hypertensive, whereas no others were hypertensive. After caffeine ingestion, 19% of the high-normal, 15% of the stage 1, and 89% of the diagnosed hypertensive groups fell into the hypertensive range. All subjects from the optimal and normal groups remained normotensive. We conclude that hypertension risk status should take priority in future research regarding pressor effects of dietary intake of caffeine.


Key Words: caffeine • diet • hypertension, detection and control • blood pressure


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Caffeine is the most widely used pharmacologically active substance in the world, with a reported intake of 200 to 300 mg/d in 80% of adults in the United States.1 Caffeine is consumed in coffee, tea, soft drinks, and, more recently, caffeinated bottled water. The mass appeal of caffeine could have health implications because of its well-documented pressor effect. A recent meta-analysis of controlled clinical trials reported a positive relationship between cups of coffee consumed on a daily basis and elevated systolic blood pressure (SBP), independent of age.2

Studies in our laboratory and others have reported that caffeine acutely elevates SBP and diastolic blood pressure (DBP) at rest and during mental and exercise stress.3 4 5 6 7 8 9 10 11 12 13 14 We have shown that this pressor effect is due to the elevation by caffeine of peripheral vascular resistance rather than enhancement of cardiac output.3 4 13 14 The ability of caffeine to increase vascular resistance raises the question of its effect in hypertension development. A recent ambulatory study of older men and women reported no difference between normotensive abstainers and coffee drinkers in 24-hour BP. However, in hypertensives, ambulatory BP increased in coffee drinkers and decreased in abstainers regardless of medication status.15

One way to document the effects of caffeine in hypertension is to examine its pressor effects on persons at different levels of risk for the disease. In separate studies, we have documented greater effects of caffeine in high-risk normotensives, borderline hypertensives, and unmedicated mild hypertensives compared with normotensives with a negative family history and low-normal resting BP levels.3 13 14 However, these results were analyzed and reported separately, making it difficult to compare BP effects quantitatively across risk groups. Therefore, we have taken our collective database, which consists of 182 persons, and classified the subjects according to the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)16 criteria into 5 separate risk groups varying from optimal to diagnosed hypertensive. With these groups, we present a comparison of BP responses to caffeine in the laboratory setting.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Overview
Although the studies from which these data were drawn differed in some particulars, all had a common core of methods, including double-blind placebo crossover designs, consistent doses of caffeine (3.3 mg/kg, average 260 mg/person),3 13 14 or a fixed dose of 250 mg (W.R. Lovallo, B.H. Sung, T.R. Hartley, T. Thomas, B.S. McKey, T.L. Whitsett, M.F. Wilson, unpublished data, 1999). BPs were measured after 20 minutes of rest and again at 45 to 60 minutes after the oral administration of caffeine.

Subjects
Five hypertension risk groups were identified during preliminary screening sessions according to the following JNC VI16 criteria: (1) optimal, SBP <120 mm Hg and DBP <80 mm Hg; (2) normal, SBP 120 to 129 mm Hg or DBP 80 to 84 mm Hg; (3) high-normal, SBP 130 to 139 mm Hg or DBP 85 to 89 mm Hg; (4) stage 1, SBP 140 to 159 mm Hg or DBP 90 to 99 mm Hg; and (5) diagnosed hypertension, recruited from a hypertension clinic.

All subjects were men in otherwise good health on the basis of physical examination and medical history. Among diagnosed hypertensives, 11 men were taking ACE inhibitors (n=7), ß-blockers (n=2), or hydrochlorothiazide (n=2). All hypertensive medications were tapered accordingly before the BP screening. Seven men from the clinic were recently diagnosed but not yet medicated.

Protocol
In all experiments, subjects were directed to abstain from caffeine after supper on the evening before coming to the laboratory, which was a period of >=12 hours. Because caffeine naiveté could be an issue, we examined any available self-reports of actual time of abstention. Reports were available for 33 in the optimal group, 18 in the normal group, 18 in the high-normal group, and 12 stage 1 men. The average time of abstention was 17.75 hours, and a 1-way ANOVA revealed no group differences (F3,77=0.69, P<0.56). Although self-reports were not available from 1 study,13 the subjects were daily caffeine users and their instructions were identical to those of the other studies, suggesting that the time of abstention was approximately the same. Moreover, the control subjects13 also had optimal or normal screening BPs and their BP responsivity to the acute dose of caffeine was no different than that of other optimal or normal groups, suggesting that the duration of caffeine abstinence (12 to 18 hours) was not different.

All procedures involved BP cuff placement followed by semisupine rest for 20 minutes, after which baseline BPs were obtained with a Dinamap Vital Signs Monitor (model 1896)3 14 (W.R. Lovallo, B.H. Sung, T.R. Hartley, T. Thomas, B.S. McKey, T.L. Whitsett, and M.F. Wilson, unpublished data, 1999) or a Paramed monitor.13 Caffeine administration was followed by 45 to 60 minutes of absorption, and postcaffeine BP readings were taken as described3 13 14 (W.R. Lovallo, B.H. Sung, T.R. Hartley, T. Thomas, B.S. McKey, T.L. Whitsett, and M.F. Wilson, unpublished data, 1999).

Caffeine Administration
In 3 of the studies,3 13 14 volunteers consumed unsweetened grapefruit juice mixed with 3.3 mg/kg caffeine (anhydrous, USP; Amend Drug Co) or they drank grapefruit juice alone (placebo). In the fourth study, volunteers took a capsule containing caffeine (250 mg plus lactose) or a placebo capsule (lactose) (W.R. Lovallo, B.H. Sung, T.R. Hartley, T. Thomas, B.S. McKey, T.L. Whitsett, and M.F. Wilson, unpublished data, 1999). The 3.3 mg/kg dose resulted in a mean dose of 260 mg/kg, closely comparable to the fixed 250 mg dose. Prior analyses have shown that small differences of this sort or minor differences in blood concentrations between volunteers did not materially affect the BP responses observed.9

Statistical Analysis
Characteristics of the risk groups were compared with the use of 1-way ANOVAs on the following variables: age (years), height (inches), weight (lb), body mass index ([BMI] weightx703/height2), reported chronic caffeine intake (mg/d), screening BPs, and predrug baseline BPs. Note that predrug baseline BPs are lower overall than screening BPs. We attribute this in part to a difference in posture and in part as a function of resting time.

The pre-to-postdrug caffeine BP effects were examined with paired samples t tests for each group. Predrug baseline BPs were examined with MANOVA with hypertension status as between-subject factors and SBP and DBP as dependent variables. Because group predrug BPs differed significantly, the main analysis of between-subject effects was accomplished with ANCOVA with postcaffeine BPs as dependent variables and baseline BPs as covariates. Finally, we used hierarchical multiple regression analyses with change scores (precaffeine and postcaffeine BPs) as dependent variables and risk group, BMI, and age as independent variables.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Caffeine raised both SBP and DBP (P<0.0001) in all groups, and effect sizes were large (d>=0.92), with the exception of pre-to-post SBP and DBP in the optimal group, which had medium effect sizes (d=0.72 and 0.77), respectively (Figure 1). However, ANCOVA revealed that the largest BP response occurred in diagnosed hypertensive men, followed by stage I and high-normal groups and then by optimal and normal groups (SBP, F4,175=5.06, P<0.001; DBP, F4,175=3.02, P<0.02). Indeed, diagnosed hypertensive men had SBP and DBP responses >1.5 times greater than the optimal group, indicating differential sensitivity to caffeine in those with hypertension.



View larger version (62K):
[in this window]
[in a new window]
 
Figure 1. Difference between precaffeine and postcaffeine SBP and DBP values by hypertension (Htn) status group, not adjusted for baseline differences.

Table 1 displays demographic characteristics of the risk groups. Groups were similar in height and reported caffeine intake. The diagnosed hypertensive men were older and heavier and had a correspondingly greater BMI. Screening DBPs were different among all groups ascending from the optimal group to the diagnosed hypertensive group. Screening SBPs followed a similar pattern except that the stage I and diagnosed hypertensive groups were the same. During testing, predrug baseline SBP and DBP values differed among the groups, with the exception of high-normal and stage I group men, for whom the values were statistically identical. Note that the predrug baseline BPs were lower overall than the screening BPs. During screening, subjects rested in a seated position for 5 minutes before and during BP readings. During the study proper, all readings were taken after 20 minutes of rest while the subject was semisupine.


View this table:
[in this window]
[in a new window]
 
Table 1. Subject Characteristics and Predrug Baseline BPs for Hypertension Status Group

Because age and BMI may affect BP independent of any caffeine effects, group BP response to caffeine was tested after control for these factors with a multiple regression analysis. The best predictor of SBP responsivity was hypertension group status (r=0.24, P<0.001). Likewise, hypertension status was the best predictor of DBP responsivity (r=0.23, P<0.002). Effect sizes for both measures were large (d=0.95). Other single variables, including BMI and age, failed to produce a significant increment in the explained proportion of BP response beyond hypertension status alone.

The potential clinical relevance of the BP response to caffeine was examined in each group by tabulating BPs that reached the hypertensive range (SBP >=140 mm Hg, DBP >=90 mm Hg, or both). Because no optimal or normal subjects reached the hypertensive range, we collapsed them into 1 group for purposes of this particular analysis. As shown in Figure 2 and Table 2, the number of persons with BPs in the stage I and stage II hypertension range after caffeine increased across risk groups. We examined these hypertensive responses with a multiple regression analysis. Hypertensive status again was the single best predictor of a hypertensive response to caffeine (r=0.64, P<0.0001); however, age (r=0.40, P<0.0001) added to the increment in the explained proportion of hypertensive response. The effect size was medium (d=0.55).



View larger version (33K):
[in this window]
[in a new window]
 
Figure 2. Precaffeine and postcaffeine baseline SBPs and DBPs. After overnight abstinence and 20 to 30 minutes of rest, 78% of subjects from the diagnosed hypertensive group and 4% of stage 1 men had blood pressures in the hypertensive range, whereas no others did. After caffeine ingestion, however, 19% of high-normal subjects, 15% of stage I subjects, and 89% of diagnosed hypertensive subjects were in the hypertensive range (stage I SBP 140 to 159 mm Hg or DBP 90 to 99 mm Hg, stage II SBP 160 to 179 mm Hg or DBP 100 to 109 mm Hg).16 Because no men from the optimal or normal groups reached the hypertensive range, we collapsed them into a single group. Htn indicates hypertension.


View this table:
[in this window]
[in a new window]
 
Table 2. Percentage of Subjects by Risk Group Who Exhibited BP in the Hypertension Range Before and After Caffeine


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
To our knowledge, this is the first quantitative examination of the pressor effects of caffeine across hypertension risk groups. The present study demonstrates that caffeine affects persons to a progressively greater degree according to their BP classification. It further demonstrates that the higher the risk classification, the more likely are BPs in the hypertensive range 45 to 60 minutes after consumption of a dietary dose of caffeine and while resting.

Although the present study does not directly address issues about tolerance to the pressor effects of caffeine, the results are not altogether unrelated. Most recent long-term studies have shown an independent positive association of caffeine consumption and higher BP, indicating that tolerance to caffeine is not complete.2 Several short-term studies have also provided evidence that tolerance is not complete.17 Moreover, the present study illustrates consistent, large BP responses to caffeine in habitual users given a morning dose equivalent to 2 to 3 cups of coffee after a brief overnight abstinence, an abstinence that reasonably mimics typical use patterns. Clearly, any degree of tolerance in these long-term users did not negate acute BP responses to caffeine.

The present study shows that chronic elevations in BP associated with a greater risk for hypertension are accompanied by increasingly large BP responses to acute doses of caffeine. These findings suggest that caffeine may exert greater BP effects in those with a greater risk of hypertension. Table 2 indicates a progressive increase across risk groups in the percentage of men with high-normal or stage I and diagnosed hypertensive BPs after caffeine.

We acknowledge several limitations to the present study. This is not a study of the long-term effects of caffeine; rather, the data are based on multiple BP readings taken 45 to 60 minutes after caffeine ingestion. In addition, under some circumstances, the acute effects of a pharmacologically active substance may be opposite in direction to longer-term actions. Indeed, the entire area of the relationship of caffeine use to BP is controversial. Although evidence we cited showed long-term pressor effects (trials ranged from 14 to 79 days)2 and incomplete tolerance to the effects of caffeine,17 the epidemiological evidence does not consistently support a relationship of caffeine to the usual sequelae of higher BP, such as stroke, myocardial infarction, or total mortality. However, other investigators have commented on potential causes for inconsistencies in these studies, including differences in research design, inadequate control of confounders, population differences, and problems associated with the measurement of chronic caffeine consumption (see James17 ).

Another possible limitation to our study concerns the diagnosed hypertensive group. These men may have exhibited exaggerated responses in part because they were withdrawn from medication. However, other research has shown that acutely administered caffeine raises BP in the presence of ß-blockade and in hypertensives taking diuretics.18 19 It is likely, then, that the responses of the diagnosed hypertensives would be similar with or without medication.

Findings from the present study support the need for further research concerning the accuracy of diagnosis for hypertension. For example, JNC VI guidelines call for patients to refrain from smoking or ingesting caffeine during the 30 minutes preceding BP measurement. All 5 groups in our study showed BP elevations from 45 to 60 minutes after caffeine ingestion and while resting, indicating that possible confounds in measurement could occur for at least double the suggested 30-minute abstinence from caffeine. In addition, further controlled studies are called for to examine whether the differential acute effects we have seen across groups manifest chronically even in small elevations of BP, which could shift upward the risk distribution for cardiovascular disease. It has been calculated that a 2 to 3 mm Hg reduction in those with a high-normal BP should result in a 25% to 50% decrease in the incidence of hypertension.20 21 22

In summary, the present findings show progressively larger BP responses to caffeine in persons with increasing risk of hypertension. Future research should focus on those with elevated BP and both treated and untreated hypertensives. Because the discrepancy in BP between the genders narrows in later life, priority should also be given to postmenopausal women in regard to dietary caffeine use.


*    Acknowledgments
 
This work was supported by the Medical Research Service of the Department of Veterans Affairs, the Oklahoma Center for the Advancement of Science and Technology, and the National Heart Lung, and Blood Institute (grants HL-32050 and HL-07640). We thank Terrie Thomas, Judith Silverstein, and Preeti Joseph for their skillful assistance in compiling databases.

Received December 27, 1999; first decision January 10, 2000; accepted January 27, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Gilbert RM. Caffeine consumption. In: Spiller GA, ed. The Methylxanthine Beverages and Foods: Chemistry, Consumption, and Health Effects. New York, NY: Alan R Liss; 1984:185–214.

2. Jee SH, He J, Whelton PK, Suh I, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension. 1999;33:647–652.[Abstract/Free Full Text]

3. Pincomb GA, Lovallo WR, McKey BS, Sung BH, Passey RB, Everson SA, Wilson MS. Acute blood pressure elevations with caffeine in men with borderline systemic hypertension. Am J Cardiol. 1996;77:270–274.[Medline] [Order article via Infotrieve]

4. Pincomb GA, Lovallo WR, Passey RB, Whitsett TL, Silverstein SM, Wilson MF. Effects of caffeine on vascular resistance, cardiac output and myocardial contractility in young men. Am J Cardiol. 1985;56:119–122.[Medline] [Order article via Infotrieve]

5. Pincomb GA, Lovallo WR, Passey RB, Wilson MF. Effect of behavior state on caffeine’s ability to alter blood pressure. Am J Cardiol. 1988;61:798–802.[Medline] [Order article via Infotrieve]

6. Pincomb GA, Wilson MF, Sung BH, Passey RB, Lovallo WR. Effects of caffeine on pressor regulation during rest and exercise in men at risk for hypertension. Am Heart J. 1991;122:1107–1115.[Medline] [Order article via Infotrieve]

7. Sung BH, Lovallo WR, Pincomb GA, Passey RB, Wilson MF. Effects of caffeine on blood pressure response during exercise in normotensive young men. Am J Cardiol. 1990;65:909–913.[Medline] [Order article via Infotrieve]

8. Pincomb G, Sung B, Sausen K, Lovallo W, Wilson M. Consistency of cardiovascular response pattern to caffeine across multiple studies using impedance and nuclear cardiography. Biol Psychol. 1993;36:131–138.[Medline] [Order article via Infotrieve]

9. Whitsett TL, Manion CV, Christensen HD. Cardiovascular effects of coffee and caffeine. Am J Cardiol. 1984;53:918–922.[Medline] [Order article via Infotrieve]

10. Lane JD, Williams RB. Cardiovascular effects of caffeine and stress in regular coffee drinkers. Psychophysiology. 1987;24:157–164.[Medline] [Order article via Infotrieve]

11. Robertson D, Frolich JC, Carr K, Watson JT, Hollifield JW, Shand DG, Oates JA. Effects of caffeine on plasma renin activity, catecholamines, and blood pressure. N Engl J Med. 1978;298:181–186.[Abstract]

12. Smits P, Thien T, van’t Larr A. Circulatory effects of coffee in relation to the pharmacokinetics of caffeine. Am J Cardiol. 1985;56:958–963.[Medline] [Order article via Infotrieve]

13. Sung BH, Lovallo WR, Whitsett T, Wilson MF. Caffeine elevates blood pressure response to exercise in mild hypertensive men. Am J Cardiol. 1995;8:1184–1188.

14. Lovallo WR, Pincomb GA, Sung BH, Everson SA, Passey RB, Wilson MF. Hypertension risk and caffeine’s effect on cardiovascular activity during mental stress in young men. Health Psychol. 1991;10:236–243.[Medline] [Order article via Infotrieve]

15. Rakic V, Burke V, Beilin LJ. Effects of coffee on ambulatory blood pressure in older men and women: a randomized controlled trial. Hypertension. 1999;33:869–873.[Abstract/Free Full Text]

16. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446.[Abstract/Free Full Text]

17. James JE. Chronic effects of habitual caffeine consumption on laboratory and ambulatory blood pressure levels. J Cardiovasc Risk. 1994; 1:159–164.

18. Freestone S, Ramsay LE. Effects of caffeine and cigarette smoking on the blood pressure of untreated and diuretic-treated hypertensive patients. Am J Med. 1982;73:345–353.

19. Smits P, Hoffmann H, Thien T, Houben H, van’t Laar A. Hemodynamic and humoral effects of coffee after ß1-selective and nonselective ß-blockade. Clin Pharmacol Ther. 1983;34:153–158.[Medline] [Order article via Infotrieve]

20. Whelton PK. Epidemiology of hypertension. Lancet. 1994;344:101–106.[Medline] [Order article via Infotrieve]

21. Klag MJ, Whelton PK, Appel LJ. Effect of age on the efficacy of blood pressure treatment strategies. Hypertension. 1990;16:700–705.[Abstract/Free Full Text]

22. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
J. R Mort and H. R Kruse
Timing of Blood Pressure Measurement Related to Caffeine Consumption
Ann. Pharmacother., January 1, 2008; 42(1): 105 - 110.
[Abstract] [Full Text] [PDF]


Home page
Adv. Physiol. Educ.Home page
P. Peeling and B. Dawson
Influence of caffeine ingestion on perceived mood states, concentration, and arousal levels during a 75-min university lecture
Advan Physiol Educ, December 1, 2007; 31(4): 332 - 335.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. R. Lovallo, M. F. Wilson, A. S. Vincent, B. H. Sung, B. S. McKey, and T. L. Whitsett
Blood Pressure Response to Caffeine Shows Incomplete Tolerance After Short-Term Regular Consumption
Hypertension, April 1, 2004; 43(4): 760 - 765.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
G V Robinson, J C Pepperell, R J O Davies, and J R Stradling
Caffeine levels following treatment of obstructive sleep apnoea
Thorax, September 1, 2003; 58(9): 801 - 802.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
W. R. Lovallo and W. Gerin
Psychophysiological Reactivity: Mechanisms and Pathways to Cardiovascular Disease
Psychosom Med, January 1, 2003; 65(1): 36 - 45.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J R Stradling, J C T Pepperell, and R J O Davies
Sleep apnoea and hypertension: proof at last?
Thorax, September 1, 2001; 56(90002): ii45 - 49.
[Full Text] [PDF]


Home page
HypertensionHome page
A. Mahmud and J. Feely
Acute Effect of Caffeine on Arterial Stiffness and Aortic Pressure Waveform
Hypertension, August 1, 2001; 38(2): 227 - 231.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hartley, T. R.
Right arrow Articles by Lovallo, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartley, T. R.
Right arrow Articles by Lovallo, W. R.
Related Collections
Right arrow Health policy and outcome research
Right arrow Behavioral/psychosocial - treatment
Right arrow Other hypertension
Right arrow Hypertension - basic studies
Right arrow Other etiology
Right arrow Epidemiology